The duration of abdominal pain in Henoch-Schönlein Purpura (HSP) patients, also known as immunoglobulin A vasculitis (IgAV) or Allergic Purpura, is a critical indicator for early intervention. This condition, affecting capillaries and small vessels, has an incidence of about 3-27/100,000 persons annually, with a relatively high occurrence in Asian populations. Skin is the most commonly affected area, with almost all patients presenting with palpable skin purpura. The disease also involves joints, gastrointestinal tract, and kidneys in varying degrees, with nervous system, lungs, and heart manifestations being relatively rare. When HSP patients exhibit predominant gastrointestinal symptoms, it is termed abdominal Henoch-Schönlein purpura (A-HSP). A-HSP typically presents with or follows cutaneous purpura, although gastrointestinal symptoms may occasionally precede skin findings. Despite being self-limiting in most patients, A-HSP varies greatly between individuals. If not managed promptly, severe complications like gastrointestinal bleeding, bowel ischemia or necrosis, and intestinal perforation may arise. Several studies have focused on early diagnosis of abdominal pain in HSP and detection of complications such as gastrointestinal bleeding or renal impairment. However, there's a lack of simple predictive models for abnormally prolonged abdominal pain in A-HSP patients, especially for those unable to undergo timely gastroscopy. Our study differs in several ways: first, it's a multi-center study, enabling investigation of a wider range of predictors and a more diverse population. Second, our predictive nomogram uses data across a broad age range, ensuring applicability in both pediatric and adult populations. This tool provides an intuitive, simple method for identifying high-risk individuals with abnormally prolonged abdominal pain duration. Third, unlike existing models primarily relying on inflammatory markers and clinical features, this study incorporates radiological imaging findings, enhancing specificity for gastrointestinal symptoms. Lastly, our focus is on abnormally prolonged abdominal pain duration as a crucial indicator for early intervention in A-HSP patients. Abdominal pain, one of the most frequent gastrointestinal manifestations, significantly increases the risk of severe complications. Monitoring its duration helps identify high-risk patients before severe complications develop, offering a critical window for timely intervention. Therefore, this study aims to identify independent risk factors for abnormally prolonged abdominal pain relief (DAPR) in A-HSP patients and develop a nomogram to assist clinical decision-making, thereby improving treatment efficacy and long-term prognosis.
